OPTION 1

LGSOC is not the same as “regular” ovarian cancer.

Low-grade serous ovarian cancer (LGSOC) is a rare, slow-growing form of the disease that often affects younger women—and it doesn’t respond well to standard chemotherapy.

📊 Key facts:

• It’s distinct from high-grade ovarian cancer

• Often diagnosed in women under 40

• Resistant to traditional chemo

• Severely underfunded

• Needs its own research

Help us shine a light on a disease too often misunderstood and overlooked.

#LGSOC #LGSOCDay #OvarianCancerAwareness #FundTheResearch #TogetherForACure

OPTION 2

​​LGSOC isn’t just rare—it’s radically under-researched.
And it affects younger people more than you’d think.

👉 1 in 10 people diagnosed with ovarian cancer are under 45.
LGSOC (low-grade serous ovarian cancer) is a type that strikes early—and hard.

🧬 There are no treatments made specifically for frontline LGSOC treatment..
Most get therapies built for other cancers—treatments that often don’t work.

💊 Fewer than 1 in 5 patients respond well to standard chemo.
Hormone and targeted therapies show promise, but we need way more research.

📉 LGSOC is usually found late, after it’s already spread. Even after treatment, 80% of cases come back.
And recurrence isn’t just a year or two away—it can happen a decade later.

🔁 That means most patients live in permanent limbo, stuck in lifelong cycles of monitoring, side effects, and uncertainty.

🎗 LGSOC deserves better.
More research. More options. More hope. Learn more at

lgsocawarenessday.org

OPTION 1

LGSOC is not the same as “regular” ovarian cancer.

Low-grade serous ovarian cancer (LGSOC) is a rare, slow-growing form of the disease that often affects younger women—and it doesn’t respond well to standard chemotherapy.

📊 Key facts:

• It’s distinct from high-grade ovarian cancer

• Often diagnosed in women under 40

• Resistant to traditional chemo

• Severely underfunded

• Needs its own research

Help us shine a light on a disease too often misunderstood and overlooked.

#LGSOC #LGSOCDay #OvarianCancerAwareness #FundTheResearch #TogetherForACure

OPTION 2

​​LGSOC isn’t just rare—it’s radically under-researched.
And it affects younger people more than you’d think.

👉 1 in 10 people diagnosed with ovarian cancer are under 45.
LGSOC (low-grade serous ovarian cancer) is a type that strikes early—and hard.

🧬 There are no treatments made specifically for frontline LGSOC treatment..
Most get therapies built for other cancers—treatments that often don’t work.

💊 Fewer than 1 in 5 patients respond well to standard chemo.
Hormone and targeted therapies show promise, but we need way more research.

📉 LGSOC is usually found late, after it’s already spread. Even after treatment, 80% of cases come back.
And recurrence isn’t just a year or two away—it can happen a decade later.

🔁 That means most patients live in permanent limbo, stuck in lifelong cycles of monitoring, side effects, and uncertainty.

🎗 LGSOC deserves better.
More research. More options. More hope. Learn more at

lgsocawarenessday.org

OPTION 1

LGSOC ≠ typical ovarian cancer.

It affects younger people, doesn’t respond well to chemo, & needs its own research funding.

Let’s raise awareness for this distinct, underfunded disease.

#LGSOC #LGSOCDay #OvarianCancerAwareness #FundTheResearch

OPTION 2:

Doing a series of Tweets, like below:

1/
LGSOC isn’t just rare.
It’s radically under-researched—and it hits younger women the hardest.
🧵

2/
1 in 10 people diagnosed with ovarian cancer are under 45.
LGSOC is a subtype that grows slowly… but strikes early.

3/
Here’s the problem:
🚫 There are no treatments made specifically for LGSOC at diagnosis.
💊 Most get therapies designed for other cancers. And they often don’t work.

4/
Only ~20% of LGSOC patients respond well to standard chemo.
Some targeted and hormone therapies are being used—but we need more data, more trials, and more funding.

5/
Most cases are diagnosed late.
And even after treatment, 80% come back.
Recurrence isn’t just a short-term risk—it can happen 10+ years later.

6/
That means lifelong follow-up. Endless scans. Uncertainty. Side effects.
This is what living with LGSOC looks like.

7/
🎗 LGSOC deserves better.
More research. More options. More hope. More action at https://www.lgsocawarenessday.org/
#LGSOCAwarenessDay #LGOSC #RareCancer #OvarianCancerAwareness #FundTheResearch

OPTION 1:

Most people have never heard of low-grade serous ovarian cancer (LGSOC)—yet it’s a distinct form of ovarian cancer that disproportionately affects younger women and is often resistant to standard chemotherapy.

It’s different from high-grade disease and needs its own research, its own studies, and its own funding.

This #LGSOCDay, let’s educate others about why LGSOC matters—and why it deserves more attention.

#LGSOC #OvarianCancerAwareness #RareCancer #WomensHealth #FundTheResearch

OPTION 2:

Low-Grade Serous Ovarian Cancer (LGSOC) is rare—but that’s not the real problem.

The real problem? It’s radically under-researched.

LGSOC often strikes younger women—and most people have never heard of it.
📊 1 in 10 people diagnosed with ovarian cancer are under 45.
🧬 Yet there are no treatments made specifically for LGSOC at the time of diagnosis.

Most patients are prescribed therapies meant for other, faster-growing cancers. But LGSOC behaves differently—and standard chemotherapy often fails.
💊 Only ~20% of patients respond well.
🔬 Hormonal and targeted therapies offer hope—but desperately need more research.

📉 Most cases are diagnosed late. Even after treatment, 80% come back.
And recurrences can happen a decade later.

This means lifelong uncertainty, relentless monitoring, and limited options for many patients.

🎗 It’s time to fund smarter research, build better treatments, and give this rare disease the attention it deserves. Learn more at

lgsocawarenessday.org

#LGSOCAwarenessDay #LGSOC #OvarianCancerAwareness #RareCancer #FundTheResearch #WomenInHealth